Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells: Its diagnostic value for endometrial carcinoma

Yoichi Kobayashi, Katsumi Tsukazaki, Kunihiko Ohta, Mikio Mikami, Kaneyuki Kubushiro, Shiro Nozawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A monoclonal antibody, MSN-1, was used for flow cytometric analysis of cells from normal endometrium, endometrial hyperplasia, and endometrial carcinoma. The 90th percentile of the specimen control was used as a threshold. Reactivity was defined by the percentage of stained cell about the thresholds, adjusted for the expected percentage. A sample was considered positive if the reactivity exceeded 10%. The positivity rate for normal endometrium, endometrial hyperplasia, and endometrial carcinoma specimens was 9.2%, 19.2%, and 84.6%, respectively. The mean (±SD) reactivity rate of MSN-1 for normal endometrium, endometrial hyperplasia, and endometrial carcinoma was 3.3 ± 6.2%, 7.4 ± 13.8%, and 34.4 ± 24.2%, respectively. There was a significant difference of the reactivity rates between normal endometrium and endometrial hyperplasia, and between endometrial hyperplasia and endometrial carcinoma (P < 0.01). In the subgroup of endometrial carcinoma patients with confined muscular invasion, the reactivity and the positivity rates were also analyzed. There was no relationship between the depth of muscular invasion and the reactivity rate or the positivity rate. In endometrial carcinoma patients who simultaneously underwent endometrial cytology, the relationship of the results of cytology and the positivity rate was also analyzed. When the results of cytology and flow-cytometric analysis were combined, the positivity rate of endometrial carcinoma was 100% (30/30). In conclusion, flow-cytometric analysis of endometrial cells employing MSN-1 could be a useful supplementary diagnostic method for endometrial carcinoma.

Original languageEnglish
Pages (from-to)23-27
Number of pages5
JournalCommunications in Clinical Cytometry
Volume30
Issue number1
DOIs
Publication statusPublished - 1997 Feb 15

Fingerprint

Endometrial Hyperplasia
Surface Antigens
Endometrial Neoplasms
Monoclonal Antibodies
Endometrium
Cell Biology

Keywords

  • cancer
  • diagnosis
  • endometrium
  • flow cytometry
  • glycolipid
  • monoclonal antibody

ASJC Scopus subject areas

  • Hematology
  • Cell Biology
  • Pathology and Forensic Medicine
  • Biophysics
  • Endocrinology

Cite this

Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells : Its diagnostic value for endometrial carcinoma. / Kobayashi, Yoichi; Tsukazaki, Katsumi; Ohta, Kunihiko; Mikami, Mikio; Kubushiro, Kaneyuki; Nozawa, Shiro.

In: Communications in Clinical Cytometry, Vol. 30, No. 1, 15.02.1997, p. 23-27.

Research output: Contribution to journalArticle

@article{b9ce5cb45a18477c9c4257e1304279fe,
title = "Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells: Its diagnostic value for endometrial carcinoma",
abstract = "A monoclonal antibody, MSN-1, was used for flow cytometric analysis of cells from normal endometrium, endometrial hyperplasia, and endometrial carcinoma. The 90th percentile of the specimen control was used as a threshold. Reactivity was defined by the percentage of stained cell about the thresholds, adjusted for the expected percentage. A sample was considered positive if the reactivity exceeded 10{\%}. The positivity rate for normal endometrium, endometrial hyperplasia, and endometrial carcinoma specimens was 9.2{\%}, 19.2{\%}, and 84.6{\%}, respectively. The mean (±SD) reactivity rate of MSN-1 for normal endometrium, endometrial hyperplasia, and endometrial carcinoma was 3.3 ± 6.2{\%}, 7.4 ± 13.8{\%}, and 34.4 ± 24.2{\%}, respectively. There was a significant difference of the reactivity rates between normal endometrium and endometrial hyperplasia, and between endometrial hyperplasia and endometrial carcinoma (P < 0.01). In the subgroup of endometrial carcinoma patients with confined muscular invasion, the reactivity and the positivity rates were also analyzed. There was no relationship between the depth of muscular invasion and the reactivity rate or the positivity rate. In endometrial carcinoma patients who simultaneously underwent endometrial cytology, the relationship of the results of cytology and the positivity rate was also analyzed. When the results of cytology and flow-cytometric analysis were combined, the positivity rate of endometrial carcinoma was 100{\%} (30/30). In conclusion, flow-cytometric analysis of endometrial cells employing MSN-1 could be a useful supplementary diagnostic method for endometrial carcinoma.",
keywords = "cancer, diagnosis, endometrium, flow cytometry, glycolipid, monoclonal antibody",
author = "Yoichi Kobayashi and Katsumi Tsukazaki and Kunihiko Ohta and Mikio Mikami and Kaneyuki Kubushiro and Shiro Nozawa",
year = "1997",
month = "2",
day = "15",
doi = "10.1002/(SICI)1097-0320(19970215)30:1<23::AID-CYTO3>3.0.CO;2-G",
language = "English",
volume = "30",
pages = "23--27",
journal = "Cytometry",
issn = "0196-4763",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Flow cytometric analysis of cell surface antigen recognized by monoclonal antibody (MSN-1) in normal, hyperplasia, and carcinoma of endometrial cells

T2 - Its diagnostic value for endometrial carcinoma

AU - Kobayashi, Yoichi

AU - Tsukazaki, Katsumi

AU - Ohta, Kunihiko

AU - Mikami, Mikio

AU - Kubushiro, Kaneyuki

AU - Nozawa, Shiro

PY - 1997/2/15

Y1 - 1997/2/15

N2 - A monoclonal antibody, MSN-1, was used for flow cytometric analysis of cells from normal endometrium, endometrial hyperplasia, and endometrial carcinoma. The 90th percentile of the specimen control was used as a threshold. Reactivity was defined by the percentage of stained cell about the thresholds, adjusted for the expected percentage. A sample was considered positive if the reactivity exceeded 10%. The positivity rate for normal endometrium, endometrial hyperplasia, and endometrial carcinoma specimens was 9.2%, 19.2%, and 84.6%, respectively. The mean (±SD) reactivity rate of MSN-1 for normal endometrium, endometrial hyperplasia, and endometrial carcinoma was 3.3 ± 6.2%, 7.4 ± 13.8%, and 34.4 ± 24.2%, respectively. There was a significant difference of the reactivity rates between normal endometrium and endometrial hyperplasia, and between endometrial hyperplasia and endometrial carcinoma (P < 0.01). In the subgroup of endometrial carcinoma patients with confined muscular invasion, the reactivity and the positivity rates were also analyzed. There was no relationship between the depth of muscular invasion and the reactivity rate or the positivity rate. In endometrial carcinoma patients who simultaneously underwent endometrial cytology, the relationship of the results of cytology and the positivity rate was also analyzed. When the results of cytology and flow-cytometric analysis were combined, the positivity rate of endometrial carcinoma was 100% (30/30). In conclusion, flow-cytometric analysis of endometrial cells employing MSN-1 could be a useful supplementary diagnostic method for endometrial carcinoma.

AB - A monoclonal antibody, MSN-1, was used for flow cytometric analysis of cells from normal endometrium, endometrial hyperplasia, and endometrial carcinoma. The 90th percentile of the specimen control was used as a threshold. Reactivity was defined by the percentage of stained cell about the thresholds, adjusted for the expected percentage. A sample was considered positive if the reactivity exceeded 10%. The positivity rate for normal endometrium, endometrial hyperplasia, and endometrial carcinoma specimens was 9.2%, 19.2%, and 84.6%, respectively. The mean (±SD) reactivity rate of MSN-1 for normal endometrium, endometrial hyperplasia, and endometrial carcinoma was 3.3 ± 6.2%, 7.4 ± 13.8%, and 34.4 ± 24.2%, respectively. There was a significant difference of the reactivity rates between normal endometrium and endometrial hyperplasia, and between endometrial hyperplasia and endometrial carcinoma (P < 0.01). In the subgroup of endometrial carcinoma patients with confined muscular invasion, the reactivity and the positivity rates were also analyzed. There was no relationship between the depth of muscular invasion and the reactivity rate or the positivity rate. In endometrial carcinoma patients who simultaneously underwent endometrial cytology, the relationship of the results of cytology and the positivity rate was also analyzed. When the results of cytology and flow-cytometric analysis were combined, the positivity rate of endometrial carcinoma was 100% (30/30). In conclusion, flow-cytometric analysis of endometrial cells employing MSN-1 could be a useful supplementary diagnostic method for endometrial carcinoma.

KW - cancer

KW - diagnosis

KW - endometrium

KW - flow cytometry

KW - glycolipid

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=0030953169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030953169&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0320(19970215)30:1<23::AID-CYTO3>3.0.CO;2-G

DO - 10.1002/(SICI)1097-0320(19970215)30:1<23::AID-CYTO3>3.0.CO;2-G

M3 - Article

C2 - 9056738

AN - SCOPUS:0030953169

VL - 30

SP - 23

EP - 27

JO - Cytometry

JF - Cytometry

SN - 0196-4763

IS - 1

ER -